SEARCH:   Advanced

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Fabry, M. E. Articles by Nagel, R. L. Search for Related Content PubMed PubMed Citation Articles by Fabry, M. E. Articles by Nagel, R. L. Related Collections Red Cells Gene Therapy Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 15 January 2001, Vol. 97, No. 2, pp. 410-418 GENE THERAPY Second generation knockout sickle mice: the effect of HbF Mary E. Fabry, Sandra M. Suzuka, Rona S. Weinberg, Christine Lawrence, Stephen M. Factor, John G. Gilman, Frank Costantini, and Ronald L. Nagel From the Departments of Medicine and Pathology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY; Mount Sinai School of Medicine, New York, NY; and Columbia University, New York, NY.     Abstract Top Abstract Introduction Materials and methods Results Discussion References Sickle transgenic mice expressing exclusively human globins are desirable for studying pathophysiology and testing gene therapy strategies, but they must have significant pathology and show evidence of amelioration by antisickling hemoglobins. Mice were generated that expressed exclusively human sickle hemoglobin with 3 levels of HbF using their previously described sickle constructs (cointegrated human miniLCR2 and miniLCRS [PNAS 89:12150, 1992]), mouse - and -globin-knockouts, and 3 different human -transgenes. It was found that, at all 3 levels of HbF expression, these mice have balanced chain synthesis, nearly normal mean corpuscular hemoglobin, and, in some cases, F cells. Mice with the least adult HbF expression were the most severe. Progressive increase in HbF from less than 3% to 20% to 40% correlated with progressive increase in hematocrit (22% to 34% to 40%) and progressive decrease in reticulocyte count (from 60% to 30% to 13%). Urine concentrating ability was normalized at high HbF, and tissue damage detected by histopathology and organ weight were ameliorated by increased HbF. The -transgene that produces intermediate levels of HbF was introduced into knockout sickle mice described by Pàszty and coworkers that express the miniLCR1GAS transgene and have fetal but not adult expression of HbF. It was found that the level of HbF required to ameliorate low hematocrit and normalize urine concentrating defect was different for the miniLCR2S and miniLCR1GAS mice. We conclude that knockout mice with the miniLCR2S transgene and postnatal expression of HbF have sufficiently faithful sickle pathology to serve as a platform for testing antisickling interventions. (Blood. 2001;97:410-418) © 2001 by The American Society of Hematology.     Introduction Top Abstract Introduction Materials and methods Results Discussion References Sickle cell disease is due to a single amino acid replacement that results in polymerization of deoxyhemoglobin and red cell sickling. Patients with the disease suffer from pleiotropic effects that impact nearly every organ in the body. Both the frequency and extent of vaso-occlusion are affected by a multitude of factors: both environmental and genetic (such as -gene cluster haplotype, -thalassemia, HbF expression, gender, and the effects of other epistatic genes). Because of the complexity of the disease, animal models are needed to dissect the mechanisms of pathology and to serve as a models for testing therapeutic strategies, including gene therapy. Some of the earliest transgenic mouse models failed to produce full-blown pathology because of absence of human , low expression of S, and/or because mouse -chains are as effective an inhibitor of polymerization as human -chains.1 Introduction of human -globin and deletion of the mouse major2-5 increased intracellular polymer formation.6 Another advance was the introduction of dominant sickle globin genes: S-Antilles7 or the recombinant construct SAD.8-11 However, mouse globins and supersickling globins can greatly complicate the interpretation of the effect of antisickling globins proposed for use in gene therapy by: (1) requiring mouse , which is an antisickling globin,1,12 for viability; (2) introducing a high or low oxygen affinity that alters the probability that S will deoxygenate and form polymer at venous pO2; and (3) altering the nucleation process that can affect the delay time and affect probability of vaso-occlusion.8 Hence, mice expressing exclusively human  and S are a desirable starting point for testing antisickling strategies. Transgenic sickle knockout mice expressing exclusively human globins have been generated.13-15 These mice represent a significant advance toward the goal of producing improved models for sickle cell disease. However, the models reported to date (including the knockout mice described by Pàszty and coworkers13 that are homozygous for both mouse - and -globin knockouts and express the transgene miniLCR 1 GAS Hba0//Hba0 Hbb0//Hbb0, hereafter referred to as BERK, have both chain imbalance and very low mean corpuscular hemoglobin (MCH) and MCH concentration (MCHC), which make their utility as models for gene therapy problematic. To create a model suitable for testing therapeutic and gene therapy strategies, we need to satisfy 2 aims: (1) produce a mouse model expressing exclusively human globins with balanced chain synthesis and normal MCH, and (2) create a series of benchmarks against which antisickling globins can be evaluated. The logical choice for the benchmark is postnatal expression of human fetal hemoglobin (22, HbF) at various levels. The models expressing exclusively human globins created to date either do not have significant postnatal expression of HbF,13-15 or express it in a number of different lines that are not strictly comparable.14 To reach these goals, we introduced the Pàszty et al -knockout13 and the Yang et al -knockout16 into mice that express our previously described sickle transgene generated by Costantini.4 This resulted in mice that can be described as miniLCR2 miniLCRS Hba0//Hba0 Hbb0//Hbb,0 hereafter referred to as NY1KO. The mice were rescued from neonatal lethality by breeding in HbF with high expression during the fetal stage and different levels of postnatal expression, which we will name, in order of increasing postnatal HbF, NY1KO L(ow), NY1KO M(edium), and NY1KO H(igh). In this paper, we demonstrate the effect of 3 levels of postnatal HbF expression on the NY1KO model and the effect of 2 different levels on the BERK model. We conclude that the NY1KO model faithfully reproduces human sickle cell anemia.     Materials and methods Top Abstract Introduction Materials and methods Results Discussion References Transgenic mice The generation of NY1 mice expressing cointegrated miniLCR2 and miniLCRS constructs was previously described by Costantini and coworkers4 and BERK mice expressing cointegrated miniLCR, 1, and GAS constructs by Pàszty and coworkers.13 Briefly, NY1 mice were generated by coinjecting 2 constructs: (1) an 8-kilobase (kb) miniLCR (locus control region) containing four 5' hypersensitive sites (HS4: HumHBB 951-2199, HS3: 4279-5128, HS2:7764-9218, HS1: 10947-15180) ligated to the SacI-SacI fragment of the human 2 globin gene (HumHBA4:3896-8147) and (2) the same miniLCR ligated to the SphI-XbaI fragment containing the S globin gene (HumHBB: 61571-65473), which then cointegrated. The BERK mice were generated by coinjecting 3 constructs: (1) a 6.4-kb miniLCR, (2) a 1.5-kb PstI fragment of the human 1 gene, and (3) a 39-kb KpnI fragment containing the human GA and S globin genes in their normal order, which then cointegrated.13 Two different -constructs were generated by Gilman et al17 (M and H) and a third construct L (F1352) was generated by Forget and coworkers,18 line 1352. The H (G100) construct17,19 consists of a fragment of HS4 (HumHBB 951-2204) that was amplified by polymerase chain reaction (PCR) from a volunteer with primer that included BglII sites and was subcloned in pbluescript II upstream of a 12.4-kb BglII fragment (which runs from HumHBB 32 837-45 203 and includes the 3' enhancer) that contains both gamma globin genes. This BglII fragment originated from a sickle cell patient with the Senegal haplotype and therefore contains a T at position 158 relative to the cap site of the G globin gene. The M (G203) construct was identical to the H construct, except that it included a PCR-generated 4.3-kb fragment (HumHBB 912-5200) containing HS 3 and 4 of the LCR instead of HS4. Injection of these constructs into fertilized mouse oocytes resulted in the production of several founder mice. One multicopy founder of each line was selected for further studies. NY1 mice were bred onto a background of C57BL/6J mice and the mouse - and -globin knockouts that have been backcrossed onto C57BL from 7 to 11 times were bred in. The mouse -globin knockout was obtained from Pàszty and coworkers.20 The mouse -globin knockout used for the NY1KO mice was obtained from Smithies et al.16 The background of the BERK mice is more complex; they have been produced, at the Albert Einstein College of Medicine (AECOM), by breeding between BERK mice with full and partial knockouts for mouse -globins and as such have a heterogenous background (including FVB/N, 129, DBA/2, C57BL/6, and Black Swiss). A limited amount of backcrossing onto C57BL has occurred at AECOM since the publication of the original description of these mice. In the BERK mice, the -globin knockout was generated by Ryan and coworkers.14 The L, M, and H mice used to produce the NY1KO mice, and the BERK M mice were backcrossed onto the C57BL background from 4 to 7 times. The breeding scheme to produce a NY1KO mouse from a founder requires one more step (to introduce the  transgene) than that used for BERK mice13 and requires fewer steps than that used for the mice described by Chang et al.15 To breed mice on a day-to-day basis the following schemes are used: (1) The NY1KO H mice breed successfully with each other. (2) For the NY1KO L and M mice, fully knocked out healthy females expressing neutral hemoglobins such as HbA (miniLCRA Hba0//Hba0 Hbb0//Hbb0), HbC, AS, or AC, and a NY1KO  male in which the  is homozygous are used. This leads to a projected breeding efficiency similar to that for the BERK mice. A large number of other less efficient schemes also produce the desired mice as well as mice useable in other contexts. All animals were maintained on "sickle chow" developed by Pàszty without added arginine and obtained from Purina (Purina Mills, St Louis, MO) as diet no. 5740C and had access to Nestlets (Ancare, Bellmore, NY) nesting material. For this paper, we studied 4 NY1KO L,10 NY1KO M, 20 NY1KO H, 20 BERK mice, and 5 BERK M mice. Mouse nomenclature Hemoglobin transgenes have a number of characteristics that will or may affect expression and potentially physiology: (1) the identity and number of hypersensitive sites in the LCR and its overall composition, (2) the number of copies, and (3) site of integration that can affect expression and cause variegation (expression in some cells and not in others).21 These features are not reflected in names that list the genes in the constructs. It is therefore important to give each transgenic line a unique and easy to remember nickname. Following the tradition of hemoglobin nomenclature, we have assigned geographical place names for the transgenes used here (except for the  transgenes) and generated 4 to 5 letter "nicknames." Table 1 lists a full description of each type of mouse.                                View this table: [in this window] [in a new window]   Table 1. Mouse nomenclature Reticulocytes, red cell indices, and smears Mice were bled from the tail (with a 2-hour recovery period under 40% oxygen) using protocols approved by the animal studies committee. Blood samples were analyzed for reticulocytes and red cell indices using the Sysmex SE 9000 system (Sysmex Corp of America, Long Grove, IL). Manual counts after staining with new methylene blue were used to validate the Sysmex reticulocyte counts in a limited number of cases, and good agreement was found. Blood smears were made from blood obtained from the tail, and dried, fixed, and stained with Giemsa. The mean corpuscular hemoglobin concentration was measured in plasma by measurement of hematocrit (MicroHematocrit, Damon/IEF Division, Needham Hights, MA) and hemoglobin concentration by diluting with Drabkins reagent and measuring the optical density at 540 nm. High-performance liquid chromatography and chain synthesis The globin composition was determined by high-performance liquid chromatography (HPLC) as previously described.22 For chain synthesis, 5 to 10 µL of washed and packed reticulocyte-enriched cells were obtained by Percoll-Larex centrifugation and added to 200 µL of the final 3H-leucine chain synthesis mix, incubated 3 hours in a shaking water bath at 37°C, and then washed and hemolyzed. Chain separation was achieved by adding 4 µL of the hemolysate to 400 µL of the HPLC starting buffer and performing reverse-phase HPLC as described above. Fractions were collected every minute and counted on an LKB 1215 Rackbeta liquid scintillation counter (Wallac Inc, Gaithersburg, MD). Reticulocyte incubation medium used: Fetal bovine serum (FBS) is dialyzed for 24 hours against Hanks balanced salt solution. The final medium: 0.5 mL FBS, 0.5 mL Dulbecco phosphate buffered saline (DPBS), 20 µL of a solution containing 1 mM of each of 19 amino acids (minus leucine), 10 µL of a 5 mg/mL solution of FeSO4.7H20, 2 mg/mL glucose, and 3.7 MBq (100 µCi) 3H-leucine.23 The percentage of newly synthesized chains was calculated by plotting counts per minute versus fraction number and determining the area under each peak. The percentage of newly synthesized -chains was calculated as a percentage of all -like chains and compared with the percentage of all -like chains determined by HPLC in peripheral blood. 2,3-Diphosphoglycerate and red cell density Sigma kit 35-A was used to determine 2,3-diphosphoglycerate (DPG) concentrations in red cells. Red cell densities were examined on Percoll/Larex gradients as previously described.24,25 Urine concentrating ability Mice were deprived of water for 8 or 24 hours in a metabolic cage as indicated. Only female mice were used because it has been previously reported, and we have confirmed, that the urine concentrating ability of male and female C57BL mice is significantly different. At the end of this period, urine was collected onto Parafilm and the osmolarity was measured after a 1:10 dilution with distilled water using a Microosmette (Precision Systems, Natic, MA). F-cell determination Cells were stained for FACS analysis with a flouresceine isothiocyanate (FITC)-conjugated monoclonal antibody specific for human -globin (a kind gift from Dr Thomas Campbell, EG&G Wallac, a Perkin-Elmer Life Science Company, Akron, OH). Histopathology Two NY1KO L mice (ages 35 and 51 days), 3 NY1KO M mice (ages 44, 65, and 167 days), and 4 NY1KO H mice (ages 87, 137, 148, and 172 days) were examined. Two BERK mice without  (ages 69 and 169 days) and 2 BERK M mice (83 and 164 days) were examined. Tissues were preserved in 10% buffered formalin. Slides were stained with hematoxylin and eosin and trichrome. One to 2 full-tissue sections per organ per animal were examined.     Results Top Abstract Introduction Materials and methods Results Discussion References High-performance liquid chromatography, reticulocytes, and red cell indices Percentage HbF was measured both by HPLC and by chain synthesis and is presented in Table 2 and Figure 4. The percentage HbF in the NY1KO L mice decreases with time, in contrast to NY1KO M and H mice, in which the percentage HbF increases with time, from a low point that occurs between 15 and 30 days of age to a plateau which is reached by about 60 days. The NY1KO M mouse has a low value about 7% HbF that increases to about 20% by 60 days (a 3-fold increase), whereas the NY1KO H mouse has a low value of about 27% that increases to about 40% by 60 days (a 1.5-fold increase). Unless otherwise noted measurements such as red cell indices and urine concentrating ability were made on mice that were 60 days of age or older.                                View this table: [in this window] [in a new window]   Table 2. Red cell indices of knockout mice Low hematocrits and high reticulocyte counts are associated with rapid red cell destruction and greater hematologic severity in humans. As HbF increases in mature NY1KO mice from less than 3% to 20% to 40% for L, M, and H mice, respectively, the reticulocyte count decreases from 63% to 30% to 13% respectively (Table 2). Hematocrit similarly increases from 22 to 34 to 41 for the same series. For BERK mice, as  increases from less than 1% to 21% for BERK and BERK M mice, reticulocyte counts remain constant at 37% and hematocrit increases from 29 to 42. Note the very low MCH of the BERK mouse (9.3 pg/cell) and that, even after M was introduced and substantially corrected chain synthesis imbalance, it is still less (10.8 pg/cell) than the MCH of thalassemic mice (12.7 pg/cell). Chain synthesis and comparison of S production between NY1 and BERK mice The results of chain synthesis experiments are given in Table 2. The ratio of all -like chains to all -like chains was measured for C57BL, NY1KO L, NY1KO M, NY1KO H, and BERK M and was found to be within the normal range for all 5 types of mouse (/ ratio of 0.93 ± 0.03). The / ratios for THAL and BERK mice determined in this laboratory (0.79 and 0.82, respectively) compared favorably with literature values (0.75-0.7826,27 and 0.79,13 respectively). Another way of looking at globin production is to breed BERK and NY1KO mice to a third transgenic and use HPLC to measure the ratio of A to S. The result of such breeding is NY1KO M × A-KO yields some mice with no , 100% human , and 50% each of A and S. BERK × A-KO yields some mice with 100% human , 75% A and 25% S where A-KO is a mouse with miniLCRA Hba0//Hba0 Hbb0//Hbb0 obtained from Ramesh Kumar (formerly of DNX, Plainsborough, NJ). In this competition, the NY1 transgene produces twice as much S as the BERK transgene. 2,3-diphosphoglycerate When deoxygenated HbS is exposed to elevated 2,3-DPG, oxygen affinity is decreased and polymer formation increases.28 Thus, elevated 2,3-DPG can increase the tendency to form polymer and potentially increase the frequency of vaso-occlusion. Mice have a higher level of 2,3-DPG than humans. Average values for human 2,3-DPG is about 10 to 15 µg/pg Hb. All mice, including the transgenic mice examined have elevated 2,3-DPG (an average of 31 ± 1.5 µg/pg Hb for C57BL and 25.5 ± 3.0 µg/pg Hb for the transgenics studied). Red cell density Within the range (less than a factor of 3 in hemoglobin concentration) and accuracy of these measurements, red cell density is directly proportional to the intracellular hemoglobin concentration or MCHC.29 Density gradients therefore provide a means of visualizing the distribution of MCHCs present in whole blood. This is particularly important in sickle cell disease because the density distribution may be not only broad (as reflected in red cell distribution width [RDW]), but is also frequently asymmetric. The presence of very dense cells, seen in NY1KO M in Figure 1, is a hallmark of sickle cell disease. The black line can be used to highlight the difference in density distribution between NY1KO M and BERK mice. View larger version (98K): [in this window] [in a new window]   Figure 1. Percoll Larex continuous density gradient of the 5 types of transgenic mice. The lightest cells (at the top of the gradient) are predominantly reticulocytes and the densest cells (at the bottom of the gradient) are enriched in ISCs. The MCHC found at each depth in the tube is displayed on the left hand side of the gradients. The gradient has physiologic pH and osmolarity and is performed at 37°C. From left to right: density-marker beads, C57BL, NY1KO L, NY1KO M, NY1KO H, BERK, and BERK M. Note the highest density (MCHC) cells in the NY1KO M mouse and the lowest density (MCHC) cells in the BERK mouse. The horizontal black line is included for reference: note in particular that about 40% of the NY1KO L red cells have a density greater than that indicated by the line, more than 90% of NY1KO M red cells have a density greater than that indicated by the line, and that less than 10% of the BERK red cells have a density greater than that indicated by the line. All 3 NY1KO mice have a fraction of cells lighter than the C57 mouse that are predominantly reticulocytes and appear in proportion to the percentage reticulocytes: 63% reticulocytes for NY1KO L (less than 3% ), 30% reticulocytes for the NY1KO M (20% ), and 13% for the NY1KO H (40% ). The percentage high-density cells is greater in the NY1KO M mouse with 20% . In contrast, the BERK mouse12 has very few red cells with a density equal to or greater than the C57 red cells. When M is introduced into the BERK mouse, red cell density increases resulting in more cells with a nearly normal MCHC; note that, in contrast to the BERK mouse, more than 90% of the red cells have a density greater than that indicated by the black line. Separation of the gradient of the BERK M mouse into a top and bottom fraction shows that there is a higher percentage  in the bottom fraction. Red cell morphology When the red cell morphology of the NY1KO M and H mice is compared with the BERK mice (Figure 2), we find results that are in agreement with the Percoll-Larex continuous density gradients (Figure 1). View larger version (125K): [in this window] [in a new window]   Figure 2. Morphology of red cells from C57BL, NY1KO H, NY1KO M, and BERK mice. (A), C57BL; (B), NY1KO H; (C), NY1KO M; and (D), BERK mice. Note that the NY1KO H mouse red cells are hyperchromic when compared with C57BL, and the BERK mouse red cells are hypochromic (open arrows). Solid arrows indicate circulating irreversibly sickled cells (ISCs) that can be found in all 3 types of transgenic mice. The red cells of the NY1KO H mouse are normochromic or hyperchromic when compared with the control C57BL mouse and, in contrast, the red cells of the BERK mouse are severely hypochromic when compared with the C57BL mouse. These results are in agreement with the Percoll-Larex continuous density gradients (Figure 1), which show that the BERK mice have a much lower MCHC than either NY1KO M or H mice. This is particularly apparent when the BERK mice are compared with the NY1KO M mice that have approximately the same average reticulocyte counts. Urine concentrating ability Urine concentrating ability after either 8 or 24 hours water deprivation is given in Table 3. We find that the BERK mouse without HbF and the NY1KO M mouse have low urine concentrating ability that suggests either chronic renal damage or red cell interference with urine concentrating ability by sickled cells. Normal urine concentrating ability is found in the NY1KO H with 40% HbF mouse and the BERK M mouse with only 20% HbF.                                View this table: [in this window] [in a new window]   Table 3. Urine concentrating ability in sickle transgenic mice F-cell determination and  levels Non-F cells (cells with no HbF) and F cells (cells with HbF) are a characteristic of human sickle cell disease. NY1KO M mice have F cells that can be readily detected by FACS analysis (Figure 3). F cells in these mice increased between day 20 and day 40 in parallel with the increase in the percentage -globin (Figure 4). BERK M mice also have F cells. NY1KO H mice have a pan-cellular distribution of HbF; that is, there is HbF in all cells. View larger version (29K): [in this window] [in a new window]   Figure 3. Comparison of distribution of  in red cells of by FACS analysis using FITC-labeled antibody specific for human  globin. Left panels, fluorescence intensity (FL1) versus cell size (which is proportional to fluorescent side scatter, FSC); right panels, number of cells versus fluorescence intensity. The same arbitrary scale is used in all 3 graphs for both FL1 and FSC. (A), NY1KO M; (B), NY1KO H; and (C), BERK M mice. Note the presence of 2 populations of red cells, one expressing  (high fluorescence intensity) and one not, in NY1KO M and BERK M mice and the small red cell size in the BERK M mice both in cells with and without  relative to the NY1KO mice. The small relative size of BERK mice is compatible with the MCVs given in Table 2. View larger version (18K): [in this window] [in a new window]   Figure 4. Percentage  versus mouse age for 3 different types of mice. Filled circles, percentage /all -like chains by HPLC; triangles, percentage F-cells by FACS; squares, percentage  by chain synthesis. Mice older than 180 days are plotted as 172 to 178 days; in this range, there was no correlation between percent HbF and age. Note that  increases with age in all mice, but that the percentage /all -like chains as measured by chain synthesis for NY1KO M does not increase with age. The most dramatic changes in percentage  occurred in mice with F-cells (both lines of mice expressing M; bottom 2 panels). The largest difference between  as measured by chain synthesis and by HPLC in peripheral blood was found in mice with F-cells. The increase in percentage  in whole blood over percentage  as measured by chain synthesis is due to increased survival of F-cells. Histopathology We compared liver, kidney, and spleen for each series of mice: the NY1KO and BERK mice (Table 4). Some comments apply to both series and all levels of HbF. In the liver, geographic lobular necrosis is observed consistent with ischemia (vascular infarction); pericentral necrosis and fibrosis are observed and are consistent with venous congestion. Hematopoiesis was most marked in NY1KO L mice and necrosis was most severe in NY1KO M mice. The spleens of all animals of both series and with all levels of HbF were grossly enlarged (Table 5), highly erythropoietic, and contained iron pigment, which is consistent with rapid red cell destruction and replacement. The number of animals in each group was relatively small (2 to 4), and animals of different ages were present in these small groups. One of the most striking observations was that there were no pathology-free animals in any of the 4 NY1KO H (the highest level of ) mice, underscoring the enhanced severity of sickle cell disease in mice.                                View this table: [in this window] [in a new window]   Table 4. Pathology of mice expressing exclusively HbS and human -chains                                View this table: [in this window] [in a new window]   Table 5. Organ weights as percentage of body weight for mice expressing exclusively human hemoglobins In the liver, NY1KO L mice had severe congestion, moderate hematopoiesis, focal areas of necrosis; NY1KO M mice had moderate-to-severe congestion, mild-to-moderate hematopoiesis, extensive necrosis with fibrosis and elevated Fe++; and NY1KO H mice had active hematopoiesis, multiple foci of necrosis, and elevated Fe++. In the kidney, NY1KO L mice had medullary congestion, focal glomerular hypercellularity, and focal interstitial fibrosis; NY1KO M mice had mild congestion, focal hypercellular glomeruli, mild-to-severe interstitial fibrosis, and focally elevated Fe++; and NY1KO H mice had focal cortical scarring, interstitial fibrosis and one case of tubular atrophy. In the spleen, NY1KO L mice had congestion, minimal fibrosis, and Fe++ pigment; NY1KO M mice had severe congestion, minimal-to-mild fibrosis, and elevated Fe++; and NY1KO H mice had mild-to-moderate congestion, mild fibrosis, and elevated Fe++. In the liver, BERK mice had severe congestion, mild-to-marked erythropoisis, mild-to-severe necrosis, fibrosis, and elevated Fe++; and BERK M mice had moderate congestion, hematopoiesis, pericentral fibrosis, and elevated Fe++. In the kidney, BERK mice had focal cortical and medullary scarring and interstitial fibrosis; and BERK M mice had medullary congestion, focal glomerular hypercellularity, and focal cortical scarring. In the spleen, BERK mice had severe congestion, mild fibrosis, and elevated Fe++; and BERK M mice had mild congestion, focal necrosis, fibrosis, and elevated Fe++.     Discussion Top Abstract Introduction Materials and methods Results Discussion References Formation of rigid polymers of deoxy HbS inside the sickle red cell result in nondeformable red cells that may block the microcirculation and undergo increased red cell destruction. The presence of fetal hemoglobin (HbF, 22) efficiently prevents polymer formation and exerts a strong protective effect in sickle cell patients both on the red cell and in prevention of end-organ damage. Transgenic mice expressing exclusively human hemoglobins developed in our laboratory (NY1KO mice) and BERK mice have severe pathology characteristic of human sickle cell disease that is ameliorated by HbF. However, less HbF is required to reduce pathology in the BERK model which we attribute, at least in part, to its thalassemic phenotype. Pathology of NY1KO and BERK mice Both the NY1KO and the BERK mouse with low levels of adult HbF expression have severe pathology characteristic of sickle cell disease that includes reticulocytosis, anemia, loss of urine concentrating ability, splenomegaly, erythroid hyperplasia in bone marrow, liver damage characteristic of ischemia, iron deposition, and evidence of chronic organ damage in multiple tissues. All the mice described here are protected by high levels of HbF expression during the fetal period. The NY1KO and the BERK models differ in MCH (which is low in thalassemia) and the ratio of newly synthesized - and -globin chains (which is 0.8 or less for -thalassemia). NY1KO mice have normal-to-near normal values for both MCH and the / ratio for chain synthesis. In contrast, the BERK mouse has low MCH and a / ratio similar to that seen in THAL mice. Both of these models, as well as those described by Ryan et al14 and Chang et al,15 are suitable for the study of pathology associated with sickle cell disease; however, the BERK and the Chang models have some characteristics of -thalassemia that may affect not only red cells, but also other organs. For example, the simultaneous presence of -thalassemic-like characteristics and HbS that may result in an environment that is highly susceptible to oxidative damage, because both syndromes are associated with free radical production. Only one of the Ryan models has been characterized for / synthesis ratio, and neither MCH nor MCHC were published for the remaining mice. HbF improves reticulocyte count, hematocrit and renal dysfunction in both NY1KO and BERK mice Increased HbF in sickle cell patients is associated with amelioration of disease and a similar effect is seen in both the NY1KO and the BERK models. Progressive increase in HbF expression in NY1KO L, M, and H mice is correlated with a large progressive increase in hematocrit and a large progressive decrease in reticulocyte count (Table 2); however, neither hematocrit nor reticulocyte counts return to the values of C57BL mice. Although NY1KO H mice have reduced pathology and organ weights, these values also do not return to those seen in C57BL mice. In contrast, in NY1KO H mice, urine concentrating ability is completely corrected. These observations suggest that HbF significantly ameliorates many aspects of pathology and that renal dysfunction is more sensitive to HbF than other properties. When M is bred into the BERK mouse, the hematocrit is significantly normalized and the urine concentrating defect is corrected, but reticulocyte count, spleen size, and other organ sizes remain high. BERK M mice have F-cells and, as in human sickle cell patients and NY1KO M mice, amelioration is observed even when HbF is heterogeneously distributed. Once again we find that renal dysfunction is more sensitive to HbF than other properties. The effect of HbF in these transgenic mice is larger and more consistent than that observed in human disease where the ameliorative effects of HbF are partially obscured by diverse epistatic effects present in the human population. Age dependence of HbF and F cells F-cell enrichment (percentage of F cells higher than percentage of F reticulocytes) occurs in sickle cell disease because HbF reduces the probability of red cell destruction. In NY1KO M mice, the age-related increase in HbF probably results from at least 2 factors: (1) selective survival of F cells and (2) increased synthesis of -chains. Chain synthesis was measured at 40 and 140 days in NY1KO M mice. At both data points, the percentage -chains by chain synthesis was twice that measured in young mice by HPLC, indicating increased -chain synthesis; and, the percentage HbF in peripheral blood by HPLC was significantly higher than the percentage measured by chain synthesis, which implies preferential survival of F cells. FACS-detectable F cells in NY1KO M mice increase with the age in tandem with the increase in the percentage HbF in peripheral blood. In contrast, the percentage HbF found by chain synthesis in NY1KO H mice is the same as that measured by HPLC in peripheral blood. This is consistent with the pan-cellular distribution of HbF demonstrated by FACS. When M is expressed in BERK mice, heterocellular expression of HbF with formation of F cells also occurs and an increase in HbF with age is also observed. The presence of F cells does not completely explain the increase in HbF with age. While in utero, mice do not have a high-oxygen affinity hemoglobin such as HbF, but instead have low production of 2,3-DPG that reaches adult levels at about 3 weeks of age.30 We speculate that low 2,3-DPG (an antisickling condition) results in reduced destruction of non-F cells during the first 2 to 3 weeks of life, both in marrow before release and as reticulocytes in peripheral blood, which may partially account for low neonatal levels of HbF. The efficacy of HbF is not the same in the NY1KO mouse and the BERK mouse In both the BERK and the NY1KO models, hematologic and physiologic pathology are reduced in proportion to expression of HbF. However, if we compare reticulocyte count, hematocrit, and urine concentrating ability, NY1KO M mice are most comparable to BERK mice; and BERK M mice are most comparable with NY1KO H mice. To understand why BERK mice with less HbF have reduced pathology compared with NY1KO mice with more HbF, we need to examine the impact of thalassemia on MCHC and, in turn, the impact of red cell MCHC on red cell survival and renal function. Thalassemia in the BERK mouse The BERK mouse has an imbalance in chain synthesis (Table 2 and Pàszty et al13) similar to that observed for THAL mice. In THAL mice, the hematologic consequences (reticulocytes 25%, Hct 32) are less severe than those reported for the BERK mouse (reticulocytes 37%, Hct 29). The THAL mouse does not have a urine concentrating defect; therefore the very significant urine concentrating defect, as well as the excess changes in reticulocyte count and hematocrit seen in the BERK mouse, can be ascribed to the presence of sickle hemoglobin. Another way of evaluating globin production is to breed the BERK and the NY1KO mice to a third knockout transgenic and measure the percentage S produced. The offspring express exclusively human hemoglobin, but the progeny of the NY1KO mice produce twice as much S as those of the BERK mice, indicating deficient S production in BERK mice. Therefore, both chain synthesis and these breeding experiments indicate that the consequences of thalassemia and its correction must be considered when HbF is introduced into the BERK mouse. MCHC and red cell density profiles MCHC plays a crucial role in the pathophysiology of sickle cell disease because the delay time for polymer formation is inversely proportional to the 30th power (and to the 15th power when nonideality effects are removed) of the concentration of deoxy HbS.31 The extent of polymer formation is directly related to the concentration of deoxy HbS. Sickle mice with low MCH and MCHC are partially protected from polymer formation. Sickle cell disease patients have red cells with a wide range of MCHCs32-34 that can be visualized by density gradient.33 The transgenic mice described here have a similar density pattern (Figure 1). Most sickle transgenic mice have elevated MCHC when compared with C57BL. This is largely due to the deoxygenation-stimulated potassium efflux that is unique to patients with sickle cell disease35 and to transgenic mice expressing S.36 The red cells of all forms of human sickle cell disease have either normal or elevated MCHC; therefore mice with low MCHC do not accurately represent the human condition. We have previously shown that inhibition of polymerization by introduction of -chains into HSDD] mice restores the density profile to that of C57BL.37 A similar effect can be seen when NY1KO M and NY1KO H mice are compared; the number of high-density cells are reduced in NY1KO H mice compared with NY1KO M mice and, at the same time, the number of light cells (reticulocytes) are also reduced because of decreased red cell destruction. In contrast, in BERK mice, the introduction of HbF increases red cell density because the founder mice have abnormally low production of hemoglobin and thalassemia. The first effect of HbF is to restore normal MCH, balanced chain synthesis, and increase MCHC. Hence, the confounding effect of HbF in BERK mice: increased HbF both inhibits polymerization and, by raising the MCHC, favors polymerization. The impact of MCHC on the relative amount of HbF required to ameliorate pathology of NY1KO and BERK mice Density gradients demonstrate that most of the red cells of the BERK mouse have lower red cell density than those of NY1KO M mouse. This implies that most of the red cells in NY1KO M mice have a higher MCHC than most of the red cells of BERK mice. Measurement of average MCHC confirms a difference of 5.5 g/dL (in agreement with the density gradient), which, in turn, implies that red cells from NY1KO M mice will have shorter delay times, more polymer formation, and produce more vaso-occlusion. Hence, it is not surprising that more HbF is required to effect a significant improvement in NY1KO M mice in selected aspects of pathology, such as urine concentrating defect or hematocrit (40% HbF for the NY1KO series versus 20% HbF for the BERK series). This observation implies that, just as in human sickle cell disease, secondary features such as thalassemia in the mouse models or -thalassemia in human patients will affect the amount of HbF required to ameliorate pathology. The very high reticulocyte count of NY1KO L and BERK mice is most likely because the increase in red cell density (MCHC) associated with both maturation and oxy/deoxy cycling results in subsequent removal of high-density cells from circulation via sickling-related processes. This hypothesis is supported by the enrichment of F cells in NY1KO M mice in which non-F cells (that have a hemoglobin composition similar to NY1KO L) are selectively removed from circulation, leaving primarily F-cells that are partially protected from polymerization by HbF. HbF is in the range of 15% to 20% in some sickle cell and So thalassemia patients, and these patients have a reduction in reticulocyte count38 without a return to normal levels. Most sickle cell patients, like some of the mice described here, have heterogeneous distribution of HbF and even at 20% HbF the disease is ameliorated but not abolished. Conclusions NY1KO and BERK mice with low HbF have severe pathology characteristic of sickle cell disease. However, BERK mice have low MCH and a thalassemia-like / ratio of chain synthesis. Pathology in both the NY1KO and BERK models is progressively ameliorated by HbF. However, introduction of HbF does not have the same effect on all measures of pathology; urine concentrating effect appears to be the most sensitive to HbF of those tested here. Furthermore, introduction of HbF does not have the same effect on all mouse models; because of lower MCHC, the BERK mouse exhibits amelioration at lower levels of HbF than the NY1KO mouse. The NY1KO mouse has 2 features that bring it closer to the human disease: (1) it has balanced chain synthesis and normal MCH at 3 different levels of HbF, and (2) the NY1KO M mouse has F cells, another feature of human sickle cell disease, which have preferential survival and should be a sensitive marker of destruction of non-F cells. The NY1KO L mouse, reported here, will be particularly suitable for breeding with mice expressing antisickling globins: The low adult HbF will not complicate interpretation, it has short survival after birth (an outcome target in itself), and it has very high reticulocyte count and low hematocrit. Comparing the effect of breeding an antisickling globin into NY1KO L mice with the effect of high adult HbF in NY1KO M and NY1KO H mice will allow the efficacy of antisickling globins to be evaluated.     Acknowledgments We thank Chris Pàszty, Oliver Smithies, Bernard Forget, and Ramesh Kumar for contributing mice with useful transgenes and knockouts and for their thoughtful suggestions. We also thank Raouf Alami and Eric Bouhassira for F-cell measurements and Thomas Campbell of Wallac, a Perkin Elmer Life Science Company, for provision of FITC-labeled -antibody.     Footnotes Submitted February 29, 2000; accepted September 18, 2000. Supported in part by NIH grants P01-HL-55435, P60-HL-38655, 1M01 RR 12248, P60-HL-28381, HL-37001, and HL63455. The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734. Reprints: Mary E. Fabry, Department of Medicine, Ullmann Room 921, Albert Einstein College of Medicine, 1300 Morris Park Ave, Bronx, NY 10461; e-mail: fabry{at}aecom.yu.edu.     References Top Abstract Introduction Materials and methods Results Discussion References 1. Rhoda MD, Domenget C, Vidaud M, et al. Mouse -chains inhibit polymerization of hemoglobin induced by human S or S-Antilles chains. Biochim Biophys Acta. 1988;952:208-212[CrossRef][Medline] [Order article via Infotrieve]. 2. Ryan TM, Behringer RR, Townes TM, Palmiter RD, Brinster RL. High-level erythroid expression of human alpha-globin genes in transgenic mice. Proc Natl Acad Sci U S A. 1989;86:37-41[Abstract/Free Full Text]. 3. Ryan TM, Townes TM, Reilly MP, Asakura T, Palmiter RP, Behringer RR. Human sickle hemoglobin in transgenic mice. Science. 1990;247:566-568[Abstract/Free Full Text]. 4. Fabry ME, Nagel RL, Pachnis A, Suzuka SM, Costantini F. High expression of human S- and -globins in transgenic mice: hemoglobin composition and hematological consequences. Proc Natl Acad Sci U S A. 1992;89:12150-12154[Abstract/Free Full Text]. 5. Fabry ME, Costantini F, Pachnis A, et al. High expression of human S- and -globins in transgenic mice: erythrocyte abnormalities, organ damage, and the effect of hypoxia. Proc Natl Acad Sci U S A. 1992;89:12155-12159[Abstract/Free Full Text]. 6. Greaves DR, Fraser P, Vidal MA, et al. A transgenic mouse model of sickle cell disorder. Nature. 1990;343:183-185[CrossRef][Medline] [Order article via Infotrieve]. 7. Rubin EM, Witkowska HE, Spangler E, et al. Hypoxia-induced in vivo sickling of transgenic mouse red cells. J Clin Invest. 1991;87:639-647. 8. Trudel M, Saadane N, Garel M-C, et al. Towards a transgenic mouse model of sickle cell disease: hemoglobin SAD. EMBO J. 1991;10:3157-3168[Medline] [Order article via Infotrieve]. 9. Trudel M, De Paepe ME, Chretien N, et al. Sickle cell disease of transgenic SAD mice. Blood. 1994;84:3189-3197[Abstract/Free Full Text]. 10. De Paepe ME, Trudel M. The transgenic SAD mouse: a model of human sickle cell glomerulopathy. Kidney Int. 1994;46:1337-1345[Medline] [Order article via Infotrieve]. 11. Blouin MJ, Beauchemin H, Wright A, et al. Genetic correction of sickle cell disease: insights using transgenic mouse models. Nat Med. 2000;6:177-182[CrossRef][Medline] [Order article via Infotrieve]. 12. Roy RP, Nagel RL, Acharya AS. Molecular basis of the inhibition of beta S-chain dependent polymerization by mouse alpha-chain: semisynthesis of chimeras of human and mouse alpha-chains. Biochemistry. 1993;268:16406-16412. 13. Pàszty C, Brion CM, Manci E, et al. Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease [see comments]. Science. 1997;278:876-878[Abstract/Free Full Text]. 14. Ryan TM, Ciavatta DJ, Townes TM. Knockout-transgenic mouse model of sickle cell disease [see comments]. Science. 1997;278:873-876[Abstract/Free Full Text]. 15. Chang JC, Lu R, Lin C, et al. Transgenic knockout mice exclusively expressing human hemoglobin S after transfer of a 240-kb betas-globin yeast artificial chromosome: a mouse model of sickle cell anemia. Proc Natl Acad Sci U S A. 1998;95:14886-14890[Abstract/Free Full Text]. 16. Yang B, Kirby S, Lewis J, Detloff PJ, Maeda N, Smithies O. A mouse model for 0-thalassemia. Proc Natl Acad Sci U S A. 1995;92:11608-11612[Abstract/Free Full Text]. 17. Gilman JG. Developmental changes of human G and A and mouse embryonic y1, y2, and h1 in transgenic mice with HS4-G-A. Blood. 1995;86:648a. 18. Arcasoy MO, Romana M, Fabry ME, Skarpidi E, Nagel RL, Forget BG. High levels of human gamma-globin gene expression in adult mice carrying a transgene of deletion-type hereditary persistence of fetal hemoglobin. Mol Cell Biol. 1997;17:2076-2089[Abstract]. 19. Shear HL, Grinberg L, Gilman J, et al. Transgenic mice expressing human fetal globin are protected from malaria by a novel mechanism. Blood. 1998;92:2520-2526[Abstract/Free Full Text]. 20. Pàszty C, Mohandas N, Stevens ME, et al. Lethal alpha-thalassaemia created by gene targeting in mice and its genetic rescue. Nat Genet. 1995;11:33-39[CrossRef][Medline] [Order article via Infotrieve]. 21. Alami R, Greally JM, Tanimoto K, et al. Beta-globin YAC transgenes exhibit uniform expression levels but position effect variegation in mice. Hum Mol Genet. 2000;9:631-636[Abstract/Free Full Text]. 22. Fabry ME, Sengupta A, Suzuka SM, et al. A second generation transgenic mouse model expressing both hemoglobin S (HbS) and HbS-Antilles results in increased phenotypic severity. Blood. 1995;86:2419-2428[Abstract/Free Full Text]. 23. Alter BP, Goff SC. A murine model for the switch from fetal to adult hemoglobin during ontogeny. Blood. 1980;56:1100-1105[Abstract/Free Full Text]. 24. Fabry ME, Mears JG, Patel P, et al. Dense cells in sickle cell anemia: the effects of gene interaction. Blood. 1984;64:1042-1046[Abstract/Free Full Text]. 25. Fabry ME, Romero J, Buchanan ID, et al. Rapid increase in red blood cell density driven by K:Cl cotransport in a subset of sickle cell anemia reticulocytes and discocytes. Blood. 1991;78:217-225[Abstract/Free Full Text]. 26. Skow LC, Burkhart BA, Johnson FM, et al. A mouse model for beta-thalassemia. Cell. 1983;34:1043-1052[CrossRef][Medline] [Order article via Infotrieve]. 27. Sauvage C, Rouyer-Fessard P, Beuzard Y. Improvement of mouse beta thalassaemia by hydroxyurea. Br J Haematol. 1993;84:492-496[Medline] [Order article via Infotrieve]. 28. Poillon WN, Robinson MD, Kim BC. Deoxygenated sickle hemoglobin: modulation of its solubility by 2,3-diphosphoglycerate and other allosteric polyanions. J Biol Chem. 1985;260:13897-13900[Abstract/Free Full Text]. 29. Fabry ME, Nagel RL. The effect of deoxygenation on red cell density: significance for the pathophysiology of sickle cell anemia. Blood. 1982;60:1370-1377[Free Full Text]. 30. Scott AF, Bunn HF, Brush AH. Functional aspects of hemoglobin evolution in the mammals. J Mol Evol. 1976;8:311-316[CrossRef][Medline] [Order article via Infotrieve]. 31. Eaton WA, Hofrichter J. Sickle cell hemoglobin polymerization. Adv Protein Chem. 1990;40:63-279[Medline] [Order article via Infotrieve]. 32. Bertles JF, Milner PFA. Irreversibly sickled erythrocytes: a consequence of the heterogeneous distribution of hemoglobin types in sickle-cell anemia. J Clin Invest. 1968;47:1731-1741. 33. Fabry ME, Nagel RL. Heterogeneity of red cells in the sickler: a characteristic with practical clinical and pathophysiological implications. Blood Cells. 1982;8:9-15[Medline] [Order article via Infotrieve]. 34. Ballas SK, Smith ED. Red blood cell changes during the evolution of the sickle cell painful crisis. Blood. 1992;92:2154-2163. 35. Tosteson DC, Carlsen E, Dunham ET. The effect of sickling on ion transport: I, the effect of sickling on potassium transport. J Gen Physiol. 1955;39:31-53[Abstract/Free Full Text]. 36. Romero J, Fabry ME, Suzuka SM, Nagel RL, Canessa M. Red blood cells of a transgenic mouse expressing high levels of human hemoglobin S exhibit deoxy-stimulated cation flux. J Membr Biol. 1997;159:187-196[CrossRef][Medline] [Order article via Infotrieve]. 37. Fabry ME, Suzuka SM, Rubin EM, Costantini F, Gilman J, Nagel RL. Strategies for amelioration of sickle cell disease: use of transgenic mice for validation of anti-sickling strategies. In: Beuzard Y,Lubin B,Rosa J, eds. Sickle Cell Disease and Thalassemias: New Trends in Therapy. Vol 234. London, UK: John Libbey Eurotext Ltd; 1995:253-262 38. Gill FM, Sleeper LA, Weiner SJ, et al. Clinical events in the first decade in a cohort of infants with sickle cell disease. Cooperative Study of Sickle Cell Disease. [Review]. Blood. 1995;86:776-783[Abstract/Free Full Text]. 39. Ciavatta DJ, Ryan TM, Farmer SC, Townes TM. Mouse model of human beta zero thalassemia: targeted deletion of the mouse beta maj- and beta min-globin genes in embryonic stem cells. Proc Natl Acad Sci U S A. 1995;92:9259-9263[Abstract/Free Full Text]. © 2001 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: A. Perumbeti, T. Higashimoto, F. Urbinati, R. Franco, H. J. Meiselman, D. Witte, and P. Malik A novel human gamma-globin gene vector for genetic correction of sickle cell anemia in a humanized sickle mouse model: critical determinants for successful correction Blood, August 6, 2009; 114(6): 1174 - 1185. [Abstract] [Full Text] [PDF] D. K. Kaul, X. Zhang, T. Dasgupta, and M. E. Fabry Arginine therapy of transgenic-knockout sickle mice improves microvascular function by reducing non-nitric oxide vasodilators, hemolysis, and oxidative stress Am J Physiol Heart Circ Physiol, July 1, 2008; 295(1): H39 - H47. [Abstract] [Full Text] [PDF] R. Kiefmann, J. M. Rifkind, E. Nagababu, and J. Bhattacharya Red blood cells induce hypoxic lung inflammation Blood, May 15, 2008; 111(10): 5205 - 5214. [Abstract] [Full Text] [PDF] E. A. Manci, C. A. Hillery, C. A. Bodian, Z. G. Zhang, G. A. Lutty, and B. S. Coller Pathology of Berkeley sickle cell mice: similarities and differences with human sickle cell disease Blood, February 15, 2006; 107(4): 1651 - 1658. [Abstract] [Full Text] [PDF] H. Beauchemin, M.-J. Blouin, and M. Trudel Differential Regulatory and Compensatory Responses in Hematopoiesis/Erythropoiesis in {alpha}- and {beta}-Globin Hemizygous Mice J. Biol. Chem., May 7, 2004; 279(19): 19471 - 19480. [Abstract] [Full Text] [PDF] K. A. Pritchard Jr., J. Ou, Z. Ou, Y. Shi, J. P. Franciosi, P. Signorino, S. Kaul, C. Ackland-Berglund, K. Witte, S. Holzhauer, et al. Hypoxia-induced acute lung injury in murine models of sickle cell disease Am J Physiol Lung Cell Mol Physiol, April 1, 2004; 286(4): L705 - L714. [Abstract] [Full Text] [PDF] J. R. Romero, S. M. Suzuka, R. L. Nagel, and M. E. Fabry Expression of HbC and HbS, but not HbA, results in activation of K-Cl cotransport activity in transgenic mouse red cells Blood, March 15, 2004; 103(6): 2384 - 2390. [Abstract] [Full Text] [PDF] L. de Franceschi, A. Baron, A. Scarpa, C. Adrie, A. Janin, S. Barbi, J. Kister, P. Rouyer-Fessard, R. Corrocher, P. Leboulch, et al. Inhaled nitric oxide protects transgenic SAD mice from sickle cell disease-specific lung injury induced by hypoxia/reoxygenation Blood, August 1, 2003; 102(3): 1087 - 1096. [Abstract] [Full Text] [PDF] G. F. Atweh, J. DeSimone, Y. Saunthararajah, H. Fathallah, R. S. Weinberg, R. L. Nagel, M. E. Fabry, and R. J. Adams Hemoglobinopathies Hematology, January 1, 2003; 2003(1): 14 - 39. [Abstract] [Full Text] [PDF] M. C. Walters, A. W. Nienhuis, and E. Vichinsky Novel Therapeutic Approaches in Sickle Cell Disease Hematology, January 1, 2002; 2002(1): 10 - 34. [Abstract] [Full Text] R. Pawliuk, K. A. Westerman, M. E. Fabry, E. Payen, R. Tighe, E. E. Bouhassira, S. A. Acharya, J. Ellis, I. M. London, C. J. Eaves, et al. Correction of Sickle Cell Disease in Transgenic Mouse Models by Gene Therapy Science, December 14, 2001; 294(5550): 2368 - 2371. [Abstract] [Full Text] [PDF] This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Fabry, M. E. Articles by Nagel, R. L. Search for Related Content PubMed PubMed Citation Articles by Fabry, M. E. Articles by Nagel, R. L. Related Collections Red Cells Gene Therapy Social Bookmarking                   What's this?

	Copyright © 2001 by American Society of Hematology         Online ISSN: 1528-0020